Mean serum levels of endostatin in patients with HCC, in those with LC not accompanying HCC, and in healthy controls were 18.2 (range 2.0-35.3) ng/ml, 12.3 (range 3.1-35.8) ng/ml, and 15.2 (range 2.2-54.3) ng/ml, respectively (P = 0.22, one-way ANOVA). Serum endostatin levels did not correlate with tumor stage (P -0.61. one-way ANOVA). histological grade (P = 0.45, one-way ANOVA), and background liver stage {P = 0.61, Student's /-test). Serum endostatin levels before and after complete removal of tumors were not significantly different (P = 1.0, Student's r-test) ( Table 1) .
Mean serum levels of VEGF in patients with HCC, in those with LC not accompanying HCC, and in healthy controls were 161 (range 23-1000) pg/ml, 103 (range 40.5-250) pg/ml, and 216 (range 40-590) ng/ml, respectively (P -0.30, one-way ANOVA). Serum VEGF levels did not correlate with histological grade (P = 0.11, one-way ANOVA) and background liver stage (P = 0.60, Student's r-test). Serum VEGF levels before and after complete removal of tumors were not significantly different (P = 0.37, Student's /-test). In contrast with endostatin level, patients with metastasis (stage IVB) had higher serum VEGF levels than those without metastasis (stage I, II, III, and IVA) (P < 0.01, one-way ANOVA) ( Table 1) .
Our data suggest that serum levels of endostatin might not demonstrate its activity in patients with HCC, consistent with Hefler's data dealing with vulvar cancers [6] . In contrast, high serum VEGF might indicate that the disease is accompanied with metastasis. Because circulating VEGF has been reported to be released from platelets [7] , high VEGF in patients with metastasis might be produced by aggregated platelets at metastatic sites. In addition, there might be little possibility that HCC secretes enough endostatin and VEGF to change their serum concentrations.
Although serum levels of endostatin might not be suitable to discuss its antiangiogenic properties in HCC patients, how much dosage would be sufficient to prevent angiogenesis in clinical trials is another question. Further investigation is Table 1 . Mean levels of serum endostatin and VEGF in patients with HCC.
Total
Control (n = 10) Phase II trial of low-dose cyclophosphamide, leucovorin, high-dose 5-fluorouracil 24-hour continuous infusion and tamoxifen in advanced biliary tract cancer Adenocarcinoma of the biliary tract include tumors which arise from the epithelium of the intrahepatic and extrahepatic bile ducts (cholangiocarcinoma) as well as from the gallbladder. Due to the lack of characteristic early symptoms, a definitive diagnosis is often established at an advanced stage, and the prognosis of patients with inoperable tumors remains dismal [1] . Because of its poor effectiveness chemotherapy must be considered experimental in this disease. In gastrointestinal malignancies clinical treatment with low doses of cyclophosphamide (C) showed an immunostimulating potency without enhanced side effects [2] . The modulation of 5-fluorouracil (5-FU) (F) by leucovorin (L) via the ternary complex formed with thymidilate synthase has been studied extensively. Theoretical the continuous infusion of 5-FU is more effective than bolus application [3] . In colorectal cancer biomodulation by leucovorin of weekly continuous high-dose 24-hour infusion of 5-FU enhances activity to a three fold increased response rate and to an improvement of survival compared to 5-FU bolus monotherapy [4, 5] . Estrogen receptors could be detected in cholangiocarcinoma tissue and inhibition of growth by tamoxifen (T) could be demonstrated in vitro and in vivo [6] . Furthermore, a cytotoxic synergism of tamoxifen and 5-FU is known in vitro based on modulation of cellular RNA [7, 8] . Now, a phase II trial of cyclophosphamide, leucovorin, 5-FU and tamoxifen (CLFT) was performed in patients with advanced biliary tract cancer.
Thirty patients (23 with cancer of the bile ducts and 7 with gallbladder carcinoma) were enrolled. Their median age was 60 years (range 41-78). All patients were required to have a histologically confirmed diagnosis and measurable disease. Patients received leucovorin 500 mg/m" and a 24-hour continuous infusion of 5-FU 2000 mg/m" weekly for six weeks and cyclophosphamide 300 mg/m 2 monthly. Treatment cycles were repeated every eight weeks. In addition all patients received tamoxifen 20 mg b.i.d. Patients were questioned about sideeffects by the responsible physician before each weekly dose. Treatment-related toxicities were documented using the grading of the WHO. Computed tomographic scanning and imaging of measurable disease was performed every cycle to assess tumor response based on the standard response definitions established by the WHO. Before initiating this therapy 15 patients required decompression of the biliary tree. This was performed in 12 patients endoscopically and in 3 patients percutaneously.
All patients enrolled were evaluable for response. No objective responses were observed. Median survival of all patients was 7.3 months (95% confidence interval: 3.7-11.0 months) and one-year survival rate was 26%. Survival was 5.5 months in patients with gall bladder cancer and 8.2 months in those with bile duct carcinoma (P = 0.26). Patients with decompressed biliary tree by endoscopic stenting at the beginning of the study survived 8.2 months, patients without stenting at the beginning of the study survived 6.0 months (P -0.54). No grade 4 toxic effects were observed. Grade 3 toxic effects were anemia (3%), vomiting (3%), and diarrhea (7%).
The question of the optimal choice of agents and dose schedule in the treatment of biliary tract cancer remains unresolved, since no standard regimen has emerged from the efforts undertaken so far. The most commonly used single agent has been 5-FU with response rates of 10% or less and survival times of 6 months or less [9, 10] . In this phase II study a group of 30 consecutive patients with advanced biliary tract cancer received a combination chemotherapy, based on high-dose 5-FU continuous infusion, and were followed up prospectively. The CLFT regimen is well tolerated with few toxic effects, but is unlikely to have any activity in advanced carcinomas of the biliary tract concerning overall response. 
